Press Releases Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2024 BST			5-day change	1st Jan Change
2.39 ^USD	+10.65%		+3.46%	-74.19%

06-14	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	CI
06-05	Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress	06-14	AQ
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	06-05	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24	06-04	NE
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	06-04	AQ
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting	06-03	AQ
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress	05-24	AQ
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting	05-23	AQ
Bio-Path: Q1 Earnings Snapshot	05-15	AQ
Bio-Path Holdings Reports First Quarter 2024 Financial Results	05-15	AQ
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024	05-08	AQ
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04-22	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	04-19	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04-18	AQ
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	04-18	AQ
Bio-Path Holdings Expands Global Patent Portfolio	04-15	AQ
Bio-Path Holdings Provides 2024 Clinical and Operational Update	04-02	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	03-27	NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	03-13	PU
Bio-Path Holdings Reports Full Year 2023 Financial Results	03-08	AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	03-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Press Releases

Filters